DEF: Catheter Precision Seeks 733% Share Increase for Urgent Financing

Catheter Precision, Inc. will hold a special meeting to vote on increasing authorized common stock by 733% to facilitate urgent financing needed to fund operations beyond January 2026.

Summary

• Stockholders of Catheter Precision, Inc. (VTAK) are invited to a Special Meeting on October 10, 2025, to vote on three proposals.
• The primary proposal is to amend the Certificate of Incorporation to increase authorized common stock from 60 million to 500 million shares.
• This increase is sought to provide flexibility for additional financing, which is aggressively being pursued, including private equity, registered issuances, credit facilities, convertible debt, and crypto asset treasury policy.
• The company explicitly states it will be unable to fund operations and pay obligations beyond January 2026 without a financing transaction.
• The second proposal is to ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ended December 31, 2026.
• WithumSmith+Brown, PC billed $937,584 in audit fees for 2024 and $660,872 for 2023.
• The third proposal is to approve the adjournment or postponement of the Special Meeting, if necessary, to solicit more votes for the other proposals.
• As of the record date, September 10, 2025, there were 1,487,266 shares of common stock issued and outstanding.
• The board of directors recommends voting FOR all three proposals.

Sentiment

Score: 3

Explanation: The urgent need for a massive increase in authorized shares to secure financing, coupled with the explicit statement that the company cannot fund operations beyond January 2026 without it, indicates a precarious financial position. The significant potential for dilution and the historical 'going concern' warning from a previous auditor contribute to a negative sentiment, despite the proactive pursuit of financing.

Positives

• The company is proactively seeking various financing options to ensure continued operations.
• The board is seeking stockholder ratification of the independent auditor, demonstrating good corporate governance.
• The company has engaged Alliance Advisors, LLC to assist with proxy solicitation, indicating a structured approach to shareholder engagement.

Negatives

• The company will be unable to fund its operations and pay its obligations beyond January 2026 without securing a financing transaction.
• The proposed increase in authorized shares from 60 million to 500 million (a 733% increase) indicates a high likelihood of significant future dilution for existing stockholders.
• Management notes that most currently available financing opportunities would require the issuance or potential issuance of very large amounts of common stock.
• The company has not yet reached a definitive decision on the best financing strategy and has no agreement in principle, letter of intent, or term sheet with any investors.
• A previous auditor's report (Haskell & White LLP for fiscal year ended December 31, 2021) included an explanatory paragraph expressing substantial doubt regarding the company's ability to continue as a going concern.

Risks

• Financing Risk: Inability to secure necessary financing to fund operations and pay obligations beyond January 2026.
• Dilution Risk: Future issuance of additional common stock will likely result in existing stockholders owning only a small fraction of the company's total outstanding shares, diluting voting rights, earnings per share, and book value per share.
• Market Constraints: Challenging economic environment and current market constraints make securing capital on preferred terms difficult.
• Going Concern Risk: Historical auditor reports have raised substantial doubt about the company's ability to continue as a going concern.
• Anti-Takeover Provisions: The company's charter and bylaws, along with Delaware law, contain provisions that could delay, deter, or discourage efforts to obtain control of the company, potentially limiting opportunities for a premium over market price for shares.

Future Outlook

The company's future outlook is heavily dependent on its ability to secure additional financing to fund operations beyond January 2026. Management is aggressively pursuing various capital-raising transactions, acknowledging that current market constraints may necessitate the issuance of a substantial amount of common stock. There is no guarantee that the company will succeed in securing the needed financing or that it will be on preferred terms.

Management Comments

• "We are aggressively seeking such financing."
• "Due to the challenging economic environment, we have explored and continue to explore a wide variety of possible capital-raising transactions, including but not limited to private equity offerings, registered issuances, credit facilities, and convertible debt, as well as other innovative and specialty finance strategies such as a crypto asset treasury policy."
• "Due to current market constraints, most of the opportunities currently available to the Company would require the issuance or potential issuance of very large amounts of common stock or the reserve of very large amounts of common stock."
• "The Company will be unable to fund its operations and pay its obligations beyond January 2026 unless a financing transaction is consummated."
• "We remain committed to the aggressive and creative pursuit of financing as described above, despite great challenges to securing capital on our preferred terms."
• "The Board has not yet reached a definitive decision regarding the best financing strategy; we do not have any agreement in principle, letter of intent, or term sheet with any investor or investors."
• "There is no guarantee that we will succeed in securing the financing that we need to sustain the Company or that any such financing will be on our preferred terms."

Industry Context

The company's urgent need for capital and the challenges in securing financing reflect broader difficulties faced by smaller, growth-stage companies in a tight economic environment. The exploration of diverse financing strategies, including traditional and innovative approaches like a 'crypto asset treasury policy,' highlights the pressure to adapt to market conditions and secure liquidity.

Management Changes

Corporate Governance

Related Party Transactions

• David A. Jenkins, Executive Chairman of the Board and Chief Executive Officer, and certain of his affiliates, hold $1,685,500 in total principal and accrued interest under promissory notes due in January 2026. Repayment is contingent on securing new financing or negotiating extensions.

Stakeholder Impact

• Shareholders: Significant potential for dilution of voting rights, earnings per share, and book value per share if the authorized share increase is approved and new shares are issued for financing.
• Creditors: Repayment of $1,685,500 in promissory notes held by David Jenkins and affiliates is at risk if financing is not secured by January 2026.
• Employees: The company's ability to fund operations beyond January 2026 directly impacts job security and the company's long-term viability.

Next Steps

• Hold a Special Meeting of stockholders on October 10, 2025, to vote on the proposals.
• If Proposal No. 1 is approved, file a Certificate of Amendment with the State of Delaware to increase authorized common stock.
• Announce preliminary voting results at the Special Meeting and disclose final results on a Current Report on Form 8-K within four business days.
• Continue to aggressively pursue various financing options to fund operations beyond January 2026.
• The Audit Committee will consider the stockholder vote on auditor ratification when determining the independent registered public accounting firm for the year ending December 31, 2026.

Key Dates

Recommendation

The filing reveals a critical financial situation where the company explicitly states it cannot fund operations beyond January 2026 without securing new financing. The proposed 733% increase in authorized common stock signals an intent for massive dilution, which would severely impact existing shareholders' ownership, voting power, and per-share metrics. While management is actively seeking financing, there are no definitive agreements, and the challenging market environment, coupled with a historical 'going concern' warning, suggests a high degree of uncertainty and risk. This situation points to a significant erosion of shareholder value, making a 'strong sell' recommendation appropriate for investors seeking to mitigate further losses.

Keywords

Catheter Precision, VTAK, SEC Filing, Proxy Statement, Authorized Shares, Stock Dilution, Capital Raise, Financing, Corporate Governance, Auditor Ratification, Special Meeting, Going Concern, Shareholder Vote, Medical Devices